205 related articles for article (PubMed ID: 31397525)
1. Proteogenomic discovery of cancer antigens: Neoantigens and beyond.
Kanaseki T; Tokita S; Torigoe T
Pathol Int; 2019 Sep; 69(9):511-518. PubMed ID: 31397525
[TBL] [Abstract][Full Text] [Related]
2. [Proteogenomics HLA Ligandome Analysis for Cancer Antigen Research].
Kanaseki T
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1377-1381. PubMed ID: 31530774
[TBL] [Abstract][Full Text] [Related]
3. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
4. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
Roerden M; Nelde A; Walz JS
Front Immunol; 2019; 10():3004. PubMed ID: 31921218
[TBL] [Abstract][Full Text] [Related]
5. ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.
Li Y; Wang G; Tan X; Ouyang J; Zhang M; Song X; Liu Q; Leng Q; Chen L; Xie L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):52. PubMed ID: 32241270
[TBL] [Abstract][Full Text] [Related]
6. Best practices for bioinformatic characterization of neoantigens for clinical utility.
Richters MM; Xia H; Campbell KM; Gillanders WE; Griffith OL; Griffith M
Genome Med; 2019 Aug; 11(1):56. PubMed ID: 31462330
[TBL] [Abstract][Full Text] [Related]
7. Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissue.
Hirama T; Tokita S; Nakatsugawa M; Murata K; Nannya Y; Matsuo K; Inoko H; Hirohashi Y; Hashimoto S; Ogawa S; Takemasa I; Sato N; Hata F; Kanaseki T; Torigoe T
JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34185709
[TBL] [Abstract][Full Text] [Related]
8. Characterization of CD8
Shinkawa T; Tokita S; Nakatsugawa M; Kikuchi Y; Kanaseki T; Torigoe T
Oncoimmunology; 2021 Jan; 10(1):1870062. PubMed ID: 33537174
[TBL] [Abstract][Full Text] [Related]
9. RNA editing derived epitopes function as cancer antigens to elicit immune responses.
Zhang M; Fritsche J; Roszik J; Williams LJ; Peng X; Chiu Y; Tsou CC; Hoffgaard F; Goldfinger V; Schoor O; Talukder A; Forget MA; Haymaker C; Bernatchez C; Han L; Tsang YH; Kong K; Xu X; Scott KL; Singh-Jasuja H; Lizee G; Liang H; Weinschenk T; Mills GB; Hwu P
Nat Commun; 2018 Sep; 9(1):3919. PubMed ID: 30254248
[TBL] [Abstract][Full Text] [Related]
10. Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation.
Löffler MW; Kowalewski DJ; Backert L; Bernhardt J; Adam P; Schuster H; Dengler F; Backes D; Kopp HG; Beckert S; Wagner S; Königsrainer I; Kohlbacher O; Kanz L; Königsrainer A; Rammensee HG; Stevanović S; Haen SP
Cancer Res; 2018 Aug; 78(16):4627-4641. PubMed ID: 29789417
[TBL] [Abstract][Full Text] [Related]
11. An Integrated Genomic, Proteomic, and Immunopeptidomic Approach to Discover Treatment-Induced Neoantigens.
Olsson N; Heberling ML; Zhang L; Jhunjhunwala S; Phung QT; Lin S; Anania VG; Lill JR; Elias JE
Front Immunol; 2021; 12():662443. PubMed ID: 33936100
[TBL] [Abstract][Full Text] [Related]
12. DeepHLApan: A Deep Learning Approach for Neoantigen Prediction Considering Both HLA-Peptide Binding and Immunogenicity.
Wu J; Wang W; Zhang J; Zhou B; Zhao W; Su Z; Gu X; Wu J; Zhou Z; Chen S
Front Immunol; 2019; 10():2559. PubMed ID: 31736974
[TBL] [Abstract][Full Text] [Related]
13. Proteogenomics: advances in cancer antigen research.
Kanaseki T; Torigoe T
Immunol Med; 2019 Jun; 42(2):65-70. PubMed ID: 31318319
[TBL] [Abstract][Full Text] [Related]
14. Immunogenic peptide discovery in cancer genomes.
Snyder A; Chan TA
Curr Opin Genet Dev; 2015 Feb; 30():7-16. PubMed ID: 25588790
[TBL] [Abstract][Full Text] [Related]
15. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
16. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy.
Marcu A; Bichmann L; Kuchenbecker L; Kowalewski DJ; Freudenmann LK; Backert L; Mühlenbruch L; Szolek A; Lübke M; Wagner P; Engler T; Matovina S; Wang J; Hauri-Hohl M; Martin R; Kapolou K; Walz JS; Velz J; Moch H; Regli L; Silginer M; Weller M; Löffler MW; Erhard F; Schlosser A; Kohlbacher O; Stevanović S; Rammensee HG; Neidert MC
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858848
[TBL] [Abstract][Full Text] [Related]
17. Proteogenomic discovery of neoantigens facilitates personalized multi-antigen targeted T cell immunotherapy for brain tumors.
Rivero-Hinojosa S; Grant M; Panigrahi A; Zhang H; Caisova V; Bollard CM; Rood BR
Nat Commun; 2021 Nov; 12(1):6689. PubMed ID: 34795224
[TBL] [Abstract][Full Text] [Related]
18. A proteogenomic approach to target neoantigens in solid tumors.
Verma A; Halder A; Marathe S; Purwar R; Srivastava S
Expert Rev Proteomics; 2020; 17(11-12):797-812. PubMed ID: 33491499
[TBL] [Abstract][Full Text] [Related]
19. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
[TBL] [Abstract][Full Text] [Related]
20. Neoantigens in Hematologic Malignancies.
Biernacki MA; Bleakley M
Front Immunol; 2020; 11():121. PubMed ID: 32117272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
